Cipla Resets Biosimilars Interest, Readies Respiratory-Focused JV
Executive Summary
Cipla moves beyond in-licensing approach and teams up with CDMO Kemwell to develop and progress respiratory biosimilars. Commercialization of products anticipated post 2025.
You may also be interested in...
Sun Pharma Chief: We Are Not 'All In' In Biologics
Sun stays “tentative” about a large exposure in the biosimilars segment while also outlining its approach to commercialize some diverse pipeline assets including an early stage GLP-1 receptor agonist.
Sun Pharma Chief: We Are Not 'All In' In Biologics
Sun stays “tentative” about a large exposure in the biosimilars segment while also outlining its approach to commercialize some diverse pipeline assets including an early stage GLP-1 receptor agonist.
Cipla Moves Into mRNA Arena With Stake In German Biotech Ethris
Cipla set to hold 10.35% in biotech Ethris, which is progressing inhaled mRNA-based therapies, among other key assets. The Indian firm expects its next wave of growth to come from areas like biosimilars and mRNA alongside lung leadership aspirations, putting the spotlight on the broader direction of the deal.